Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment of Malaria in Schoolchildren

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 8 to \< 14 years (boys), ≥ 8 to \< 12 years (girls)~* Student enrolled at participating school in classes 3-7~* Provision of informed consent from parent or guardian~* Provision of assent by student~Exclusion Criteria:~* Known allergy or history of adverse reaction to study medications~* Onset of menstruation (girls)~* Fever (≥ 37.5°C axillary) or history of fever in the previous 24 hours~* Evidence of severe malaria or danger signs~* Haemoglobin \< 7.0 gm/dL~* Parasite density \> 10,000/ul

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Combination of Amodiaquine +sulfadoxine-pyrimethamine (Type: ACTIVE_COMPARATOR): Combination of Amodiaquine (Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
- Dihydroartemisinin-piperaquine (Type: ACTIVE_COMPARATOR): Dihydroartemisinin-piperaquine (Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets targeting a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively, given in 3 equally divided daily doses to the nearest ¼ tablet)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (had no active ingredients, produced by Cosmos Limited, Nairobi, Kenya)
- Sulfadoxine-pyrimethamine alone (Type: ACTIVE_COMPARATOR): sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).